Intractable & Rare Diseases Research | From System Building to Global Engagement: Current Significance of and Future Directions for Rare Disease Research in China

Recommend:

This article systematically summarizes the latest progress in China's rare disease governance system construction, clinical collaboration networks, real-world data application, and multi-stakeholder engagement, proposing a global paradigm shift from single-disease research toward systemic capacity building, with significant implications for policy and scientific guidance.

 

Literature Overview

The article 'From System Building to Global Engagement: Current Significance of and Future Directions for Rare Disease Research in China,' published in Intractable & Rare Diseases Research, reviews and summarizes China's systematic efforts in recent years regarding governance frameworks, clinical collaboration networks, real-world data utilization, and multi-stakeholder engagement in rare disease research. The article points out that as rare disease treatments gradually enter clinical practice and become embedded within social systems, breakthroughs in individual diseases are no longer sufficient to address the complex challenges in the real world. Research is shifting toward a new paradigm integrating cross-system and multidisciplinary approaches. China's practices, based on its large patient population and significant regional disparities, provide new analytical perspectives and practical references for global rare disease research, promoting a transition from isolated breakthroughs to sustainable systemic capacity building.

Background Knowledge

Rare disease research has long been dominated by Western countries, focusing on gene discovery, precision diagnosis, and orphan drug development. International consortia such as IRDiRC aim to achieve molecular diagnosis for all rare genetic diseases. However, with the widespread adoption of high-throughput sequencing and increasing treatment options, research focus is expanding from mechanistic exploration to systemic issues such as healthcare policy, reimbursement mechanisms, real-world evidence (RWE), and patient engagement. Asian countries like Japan have established institutional support systems through universal health insurance and designated intractable disease programs. Due to its large population base and significant regional differences, China is still in a rapid development phase in areas such as patient registries, diagnosis and treatment networks, policy formulation, and funding mechanisms. Real-world data (RWD) and real-world evidence (RWE) are increasingly becoming essential tools to complement randomized controlled trials in rare disease research with limited sample sizes, supporting regulatory decisions and health technology assessments. Meanwhile, patient organizations are playing an increasingly structural role in setting research priorities, generating data, and providing policy feedback. Current challenges include the lack of a systemic governance framework, insufficient cross-regional collaboration, limited pathways for evidence generation, and underdeveloped patient engagement mechanisms. This study systematically reviews multidimensional progress in China’s rare disease governance system construction and proposes that future research should integrate big data, RWE, policy systems, and patient engagement to promote the sustainable evolution of the global rare disease research paradigm.

 

Can be used to preliminarily predict the phenotypes that gene knockout may produce before designing experiments.

Learn More

 

Research Methods and Experiments

This article is a guest editorial, synthesizing findings from multiple research papers in the special issue 'Rare Diseases and Orphan Drugs in China: System Building and Global Engagement' published in Intractable & Rare Diseases Research. It systematically reviews recent advances in China’s rare disease governance structures, clinical collaboration networks, real-world data applications, and multi-stakeholder engagement mechanisms. Using literature review and policy analysis, the authors compare the rare disease research trajectories of Europe, the United States, Japan, and China, with particular attention to systemic elements such as institutional design, clinical collaboration, RWD utilization, and social engagement. The article further proposes four forward-looking recommendations: formally integrating national and regional system building into research agendas, promoting diversified and contextualized evidence pathways, strengthening cross-system and cross-regional comparative studies, and recognizing the structural role of patients in rare disease science.

Key Conclusions and Perspectives

• Rare disease research is transitioning from a focus on single-disease mechanisms and drug development to a comprehensive agenda encompassing healthcare systems, policy frameworks, and patient engagement
• Systemic capacity is an indispensable component of rare disease research; the absence of robust patient registries, coordinated diagnosis and treatment networks, and coherent policy frameworks directly constrains scientific progress and clinical translation
• Real-world data and real-world evidence have become foundational in rare disease research, especially where randomized controlled trials are difficult to conduct; RWE plays an increasingly important role in regulatory decisions and health technology assessments
• Multi-stakeholder collaboration is reshaping the research ecosystem; changes in interaction patterns among patient organizations, regulators, payers, and researchers significantly influence clinical pathway development, policy decisions, and integration of patient-reported outcomes
• China’s practical experience, based on its vast patient population and significant regional disparities, offers new analytical perspectives and practical references for global rare disease research, helping to drive the paradigm shift from isolated breakthroughs to sustainable systemic capacity building

Research Implications and Outlook

The study emphasizes that effective systemic responses to rare diseases require legal and institutional frameworks as fundamental prerequisites, and policy research should be regarded as equally critical as clinical and biomedical sciences. Future research should promote diversified evidence pathways by integrating real-world evidence, health economics, and policy studies to provide more comprehensive support for orphan drug value assessment. Additionally, strengthening cross-national comparative research—particularly on differences in health insurance arrangements, regulatory frameworks, and social support systems between Asia and other regions—will offer valuable insights for global governance. The structural role of patient organizations in setting research priorities, generating data resources, and providing policy feedback has been validated in multiple countries and should be further institutionalized to enhance the social relevance, legitimacy, and credibility of research.

 

A practical tool for quickly mapping DNA or RNA sequences to the genome.

Learn More

 

Conclusion

This article systematically articulates how rare disease research is evolving from traditional single-disease mechanistic exploration and orphan drug development toward a comprehensive scientific agenda encompassing healthcare systems, policy frameworks, real-world evidence, and patient engagement. China's multidimensional practices in building rare disease governance systems—including patient registries, clinical collaboration networks, real-world data applications, and multi-stakeholder engagement mechanisms—not only address domestic gaps in systemic capacity but also offer new analytical perspectives for global research. The article emphasizes that building systemic capacity is key to achieving long-term rare disease management and clinical translation, and that real-world evidence has become a critical support for regulatory and policy decisions under limited sample sizes. Multi-stakeholder collaboration is reshaping the research ecosystem, and the structural involvement of patient organizations has significantly enhanced the social value and policy responsiveness of research. Future research should incorporate policy and institutional development into core agendas, promote diversified and contextualized evidence generation pathways, and strengthen cross-regional comparative studies. China's experience demonstrates that by integrating big data, real-world evidence, policy systems, and patient engagement, a more sustainable and impactful rare disease research system can be built, offering a new paradigm for global responses to rare disease challenges.

 

Wei Tang. From system building to global engagement: Current significance of and future directions for rare disease research in China. Intractable & Rare Diseases Research.